CRISPR Therapeutics (CRSP) stock: insider trades, news & valuation
Net sellingShare price and insider trades
CRISPR Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $50K and 5 sold $18.4M of CRSP stock on the open market.
Get emailed when insiders cluster-buy stocks like CRSP
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
CRSP insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $119K | 1 |
| Q3 2026 | — | 0 | $1.4M | 2 |
| Q2 2026 | — | 0 | $211K | 1 |
| Q1 2026 | — | 0 | $12.3M | 19 |
| Q4 2025 | — | 0 | $4.4M | 6 |
| Q3 2025 | — | 0 | — | 0 |
| Q2 2025 | $50K | 1 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 CRISPR Therapeutics AG insider reported open-market purchases totaling $50K, while 5 insiders reported sales totaling $18.4M. 12 of 29 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 8SEC | James R. KasingerGeneral Counsel | Sell Plan | 1,99094,784 held (−2%) | $60.04 | $119K | -11.1% | — |
| Sep 24SEC | James R. KasingerGeneral Counsel | Sell Plan | 10,40094,784 held (−10%) | $60.24 | $626K | -11.4% | — |
| Sep 21SEC | Ali BehbahaniDirector | Sell | 13,67916,637 held (−45%) | $57.09 | $781K | -6.5% | — |
| Jun 1SEC | Naimish PatelChief Medical Officer | Sell | 3,78619,357 held (−16%) | $55.62 | $211K | -4.0% | — |
| Mar 24SEC | Samarth KulkarniCEO | Sell | 10,020255,501 held (−4%) | $46.78 | $469K | +14.1% | — |
| Mar 24SEC | Raju PrasadCFO | Sell | 3,70815,565 held (−19%) | $46.78 | $173K | +14.1% | — |
| Mar 24SEC | James R. KasingerGeneral Counsel | Sell | 3,18294,308 held (−3%) | $46.78 | $149K | +14.1% | — |
| Mar 17SEC | Samarth KulkarniCEO | Sell | 10,349245,834 held (−4%) | $48.26 | $499K | +10.6% | — |
| Mar 17SEC | Raju PrasadCFO | Sell | 5,84817,794 held (−25%) | $48.26 | $282K | +10.6% | — |
| Mar 17SEC | Raju PrasadCFO | Sell | 4,02113,773 held (−23%) | $48.26 | $194K | +10.6% | — |
| Mar 17SEC | James R. KasingerGeneral Counsel | Sell | 3,45091,240 held (−4%) | $48.26 | $166K | +10.6% | — |
| Mar 17SEC | Naimish PatelChief Medical Officer | Sell | 3,15013,143 held (−19%) | $48.26 | $152K | +10.6% | — |
| Mar 12SEC | Samarth KulkarniCEO | Sell | 9,798235,558 held (−4%) | $52.80 | $517K | +1.1% | — |
| Mar 12SEC | James R. KasingerGeneral Counsel | Sell | 2,80087,815 held (−3%) | $52.80 | $148K | +1.1% | — |
| Feb 20SEC | Samarth KulkarniCEO | Sell | 6,967226,106 held (−3%) | $52.58 | $366K | +1.5% | — |
| Feb 20SEC | James R. KasingerGeneral Counsel | Sell | 2,11285,115 held (−2%) | $52.58 | $111K | +1.5% | — |
| Jan 27SEC | Naimish PatelChief Medical Officer | Buy | 1,508new position | $32.96 | $50K | +62.0% | — |
| Jan 26SEC | Raju PrasadCFO | Sell Plan | 34,9726,767 held (−84%) | $60.19 | $2.1M | -11.3% | — |
| Jan 22SEC | Samarth KulkarniCEO | Sell Plan | 60,000134,201 held (−31%) | $60.23 | $3.6M | -11.4% | — |
| Jan 22SEC | Samarth KulkarniCEO | Sell Plan | 21,433202,768 held (−10%) | $51.61 | $1.1M | +3.4% | — |
| Jan 22SEC | Samarth KulkarniCEO | Sell Plan | 8,567194,201 held (−4%) | $52.10 | $446K | +2.5% | — |
| Jan 8SEC | Raju PrasadCFO | Sell Plan | 18,93317,534 held (−52%) | $60.18 | $1.1M | -11.3% | — |
| Jan 8SEC | Raju PrasadCFO | Sell Plan | 5,7636,767 held (−46%) | $60.21 | $347K | -11.3% | — |
| Jan 8SEC | Raju PrasadCFO | Sell Plan | 5,00412,530 held (−29%) | $60.00 | $300K | -11.0% | — |
| Dec 23SEC | Raju PrasadCFO | Sell Plan | 5,4727,767 held (−41%) | $56.33 | $308K | -5.2% | — |
| Dec 23SEC | Raju PrasadCFO | Sell Plan | 3,52813,239 held (−21%) | $55.10 | $194K | -3.1% | — |
| Dec 23SEC | Raju PrasadCFO | Sell Plan | 1,0006,767 held (−13%) | $56.89 | $57K | -6.2% | — |
| Oct 20SEC | Samarth KulkarniCEO | Sell | 50,895254,201 held (−17%) | $67.91 | $3.5M | -21.4% | — |
| Oct 15SEC | Samarth KulkarniCEO | Sell | 4,242205,096 held (−2%) | $66.60 | $283K | -19.8% | — |
| Oct 15SEC | James R. KasingerGeneral Counsel | Sell | 1,07683,402 held (−1%) | $66.60 | $72K | -19.8% | — |
Insiders at CRISPR Therapeutics AG
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Samarth KulkarniCEO | — | $10.8M | Mar 24, 2026 | — |
| Raju PrasadCFO | — | $5.1M | Mar 24, 2026 | — |
| James R. KasingerGeneral Counsel | — | $1.4M | Oct 8, 2026 | — |
| Ali BehbahaniDirector | — | $781K | Sep 21, 2026 | — |
| Naimish PatelChief Medical Officer | $50K | $363K | Jun 1, 2026 | — |
CRSP stock: common questions
Are CRISPR Therapeutics AG insiders buying CRSP stock?
In the past 12 months, 1 insiders reported open-market purchases of CRSP worth $50K. The latest was Chief Medical Officer Naimish Patel bought $50K of CRSP at $32.96 — first open-market purchase in our records; opens a new position.
Are CRISPR Therapeutics AG insiders selling CRSP stock?
5 insiders reported sales worth $18.4M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CRSP's 52-week range?
Over the past year CRSP has traded between $44.34 and $74.92. It last closed at $53.39 on Oct 9, 2026.